Introduced Version
SENATE BILL No. 514
_____
DIGEST OF INTRODUCED BILL
Citations Affected: IC 27-8-40; IC 27-13-7-29.
Synopsis: Chimeric antigen receptor T-cell therapy. Provides that a
policy of accident and sickness insurance or health maintenance
organization contract that provides coverage for chimeric antigen
receptor (CAR) T-cell therapy may not refuse to contract or deny
coverage for the administration of any CAR T-cell therapy by any
provider that qualifies as a certified health care facility by the federal
Food and Drug Administration for the applicable CAR T-cell therapy.
Effective: July 1, 2025.
Leising
January 16, 2025, read first time and referred to Committee on Health and Provider
Services.
2025 IN 514—LS 7414/DI 141 Introduced
First Regular Session of the 124th General Assembly (2025)
PRINTING CODE. Amendments: Whenever an existing statute (or a section of the Indiana
Constitution) is being amended, the text of the existing provision will appear in this style type,
additions will appear in this style type, and deletions will appear in this style type.
Additions: Whenever a new statutory provision is being enacted (or a new constitutional
provision adopted), the text of the new provision will appear in this style type. Also, the
word NEW will appear in that style type in the introductory clause of each SECTION that adds
a new provision to the Indiana Code or the Indiana Constitution.
Conflict reconciliation: Text in a statute in this style type or this style type reconciles conflicts
between statutes enacted by the 2024 Regular Session of the General Assembly.
SENATE BILL No. 514
A BILL FOR AN ACT to amend the Indiana Code concerning
insurance.
Be it enacted by the General Assembly of the State of Indiana:
1 SECTION 1. IC 27-8-40 IS ADDED TO THE INDIANA CODE AS
2 A NEW CHAPTER TO READ AS FOLLOWS [EFFECTIVE JULY
3 1, 2025]:
4 Chapter 40. Coverage for Chimeric Antigen Receptor T-Cell
5 Therapy
6 Sec. 1. As used in this chapter, "chimeric antigen receptor T-cell
7 therapy" or "CAR T-cell therapy" means a treatment that is
8 designed to manipulate T-cell protein to recognize an antigen on
9 targeted tumor cells in an effort to eliminate cancer.
10 Sec. 2. As used in this chapter, "policy of accident and sickness
11 insurance" has the meaning set forth in IC 27-8-5-1. The term does
12 not include a policy, plan, or coverage set forth in IC 27-8-5-2.5(a).
13 Sec. 3. (a) This section applies to a policy of accident and
14 sickness insurance that is delivered, issued, or renewed after
15 December 31, 2025.
16 (b) A policy of accident and sickness insurance that provides
17 coverage for CAR T-cell therapy may not:
2025 IN 514—LS 7414/DI 141 2
1 (1) refuse to contract; or
2 (2) deny coverage;
3 for the administration of any CAR T-cell therapy by any provider
4 that qualifies as a certified health care facility in accordance with
5 the approved procedure under the CAR T-cell therapy product
6 license by the federal Food and Drug Administration for the
7 applicable CAR T-cell therapy.
8 SECTION 2. IC 27-13-7-29 IS ADDED TO THE INDIANA CODE
9 AS A NEW SECTION TO READ AS FOLLOWS [EFFECTIVE JULY
10 1, 2025]: Sec. 29. (a) This section applies to an individual contract
11 or a group contract that is entered into, amended, or renewed after
12 December 31, 2025.
13 (b) As used in this section, "chimeric antigen receptor T-cell
14 therapy" or "CAR T-cell therapy" means a treatment that is
15 designed to manipulate T-cell protein to recognize an antigen on
16 targeted tumor cells in an effort to eliminate cancer.
17 (c) An individual contract or a group contract that provides
18 coverage for CAR T-cell therapy may not:
19 (1) refuse to contract; or
20 (2) deny coverage;
21 for the administration of any CAR T-cell therapy by any provider
22 that qualifies as a certified health care facility in accordance with
23 the approved procedure under the CAR T-cell therapy product
24 license by the federal Food and Drug Administration for the
25 applicable CAR T-cell therapy.
2025 IN 514—LS 7414/DI 141